Adenovirus Vector-Mediated Gene Transfer into Human Epileptogenic Brain Slices: Prospects for Gene Therapy in Epilepsy

Experimental Neurology

Volumn 148, Issue 1, 1997, Pages 167-178

  O'Connor, William M ^a   Davidson, Beverly L ^b   Kaplitt, Michael G ^c   Abbey, Maureen V ^a   During, Matthew J ^d,e   Leone, Paola ^d,e   Langer, David ^f   O'Connor, Michael J ^a   Freese, Andrew ^a,g  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HYBRID PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BRAIN CORTEX; EPILEPSY; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; GLIA; HIPPOCAMPUS; HUMAN; HUMAN ADENOVIRUS; LACTOSE OPERON; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; POLYMERASE CHAIN REACTION; REPORTER GENE; VIROLOGY;

ADENOVIRUSES, HUMAN; ADULT; AGED; AGED, 80 AND OVER; BETA-GALACTOSIDASE; CEREBRAL CORTEX; EPILEPSY; FEMALE; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HIPPOCAMPUS; HUMANS; LAC OPERON; MALE; MIDDLE AGED; NEUROGLIA; NEURONS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 0031265905     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6658     Document Type: Article

References (117)

1. Ajmone-Marsan, C. 1991. Preoperative electroencephalographic localization of large epileptogenic zones in the frontal and temporal lobes. Can. J. Neurol. Sci. 18(Suppl 4): 564-565.
2. Akli, S., C. Caillaud, E. Vigne, et al. 1993. Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet. 3: 221-328.
3. Alam, J., and J. L. Cook. 1990. Reporter genes: Application to the study of mammalian gene transcription. Anal. Biochem. 188: 245-254.
4. Babb, T. L., and W. J. Brown. 1987. Pathological findings in epilepsy. In Surgical Treatment of the Epilepsies (J. Engel Jr., Ed.), pp. 511-540. Raven Press, New York.
5. Badie, B., K. Hunt, J. S. Economou, et al. 1994. Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model. Neurosurgery 35: 910-916.
6. Bajocchi, G., S. H. Feldman, R. G. Crystal, et al. 1993. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genet. 3: 229-334.
7. Bergold, P. J., P. Casaccia-Bonnefil, X. L. Zeng, et al. 1993. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc. Natl. Acad. Sci. USA 90: 6165-6169.
8. Betz, A. L., G-Y. Yang, and B. L. Davidson. 1995. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cereb. Blood Flow Metab. 15: 547-551.
9. Bobo, R. H., D. W. Laske, A. Akbasak, et al. 1994. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91: 2076-2080.
10. Boucher, R. C., M. R. Knowles, L. G. Johnson, et al. 1994. Gene therapy for cystic fibrosis using El-deleted adenovirus: A phase I trial in the nasal cavity: The University of North Carolina at Chapel Hill. Hum. Gene Ther. 5: 615-639.
11. Boviatsis, E. J., M. Chase, M. X. Wei, et al. 1994. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther. 5: 183-691.
12. Bowery, N. G., D. R. Hill, A. L. Hudson, et al. 1980. (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283: 92-94.
13. Breakefield, X. O., and N. A. DeLuca. 1991. Herpes simplex virus for gene delivery to neurons. New Biol. 3: 203-218.
14. Brenner, M., W. C. Kisselberth, Y. Su, et al. 1994. GFAP promoter directs astrocyte-specific expression in transgenic mice. J. Neurosci. 14: 1030-1037.
15. A receptor subtypes: From pharmacology to molecular biology. FASEB J. 5: 2916-523.
16. Caillaud, C., S. Akli, E. Vigne, et al. 1993. Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells. Eur. J. Neurosci. 5: 1287-1291.
17. Chen, S. H., H. D. Shine, J. C. Goodman, et al. 1994. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91: 3054-3057.
18. Colmers, W. R., and D. Bleakman. 1994. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17: 373-379.
19. Crystal, R. G., N. G., McElvaney, M. A. Rosenfeld, et al. 1994. Administration of an adenovirus containing the human CFTR cDNAto the regulatory tract of individuals with cystic fibrosis. Nature Genet. 8: 42-52.
20. Davidson, B. L., E. D. Allen, K. F. Kozarsky, et al. 1993. Amodel system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet. 3: 219-223.
21. Davidson, B. L., S. E. Doran, D. S. Shewach, et al. 1994. Expression of Escherichia coli β-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp. Neurol. 125: 258-267.
22. Doran, S. E., X. D. Ren, A. L. Betz, et al. 1995. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 36: 965-970.
23. Durand, D. 1993. Ictal patterns in experimental models of epilepsy. J. Clin. Neurophysiol. 10: 281-297.
24. During, M. J., A. I. Geller, A. Freese, et al. 1990. Neuronal expression of parvalbumin and calcium/calmodulin dependent protein kinase II from HSV-1 vectors. Soc. Neurosci. Abstr. 16: 216.4.
25. During, M. J., A. Freese, A. Y. Deutch, et al. 1992. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp. Neurol. 115: 193-199.
26. During, M. J., and D. D. Spencer. 1992. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32: 618-624.
27. During, M. J., J. R. Naegele, K. L. O'Malley, et al. 1994. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266: 1399-1403.
28. During, M. J., M. G. Kaplitt, A. Freese, et al. 1995. In vivo gene therapy of Parkinson's disease in a primate model. J. Neurosurg. 82: 341A.702.
29. During, M. J., K. M. Ryder, and D. D. Spencer. 1995. Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature 376: 174-177.
30. Engel, J., Jr., M. V. Driver, and M. A. Falconer. 1975. Electrophysiological correlates of pathology and surgical results in temporal lobe epilepsy. Brain 98: 129-156.
31. Engel, J., Jr., T. R. Henry, and B. E. Swartz. 1995. Positron emission tomography in frontal lobe epilepsy. Adv. Neurol. 66: 223-238.
32. Fink, D. J., L. R. Sternberg, P. C. Wever, et al. 1992. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum. Gene Ther. 3: 11-19.
33. Freese, A., A. I. Geller, and R. Neve. 1990. HSV-1 vector mediated neuronal gene delivery: Strategies for molecular neuroscience and neurology. Biochem. Phannacol. 40: 2189-2199.
34. Freese, A., and A. I. Geller. 1991. Infection of cultured striatal neurons with a defective HSV-1 vector: Implications for gene therapy. Nucleic Acids Res. 19: 7219-7223.
35. Freese, A., M. Stern, M. G. Kaplitt, et al. 1996. Prospects for gene therapy in Parkinson's disease. Mov. Disord. 11: 469-488.
36. Frim, D. M., T. A. Uhler, W. R. Galpern, et al. 1994. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA 91: 5104-5108.
37. Geller, A. I., and X. O. Breakefield. 1988. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241: 1667-1669.
38. Geller, A. I., and A. Freese. 1990. Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. Proc. Natl. Acad. Sci. USA 87: 1149.
39. Geller, A. I., M. J. During, J. W. Haycock, et al. 1993. Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector. Proc. Natl. Acad. Sci. USA 90: 7603-7607.
40. Ghadge, G. D., R. P. Roos, U. J. Kang, et al. 1995. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther. 2: 132-137.
41. Glorioso, J. C., W. F. Gorins, C. A. Meaney, et al. 1994. Gene transfer to brain using herpes simplex virus vectors. Ann. Neurol. 35(Suppl): S28-S34.
42. Goodman, J. C., T. W. Trask, S-H. Chen, et al. 1995. Toxicity of adenoviral mediated brain tumor gene therapy in primates. In Proceedings, International Conference on Gene Therapy for CNS Disorders, Abstract 2.10.
43. Gradus-Pizlo, I., R. L. Wilensky, K. L. March, et al. 1995. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J. Am. Coll. Cardiol. 26: 1549-1557.
44. Hanania, E. G., J. Kavanagh, G. Hortobagyi, et al. 1995. Recent advances in the application of gene therapy to human disease. Am. J. Med. 99: 537-552.
45. Heilig, M., and E. Widerlov. 1995. Neurobiology and clinical aspects of neuropeptide Y. Crit. Rev. Neurobiol. 9: 115-136.
46. Horellou, P., E. Vigne, M. N. Castel, et al. 1994. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 6: 49-53.
47. The International Batten Disease Consortium. 1995. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82: 949-957.
48. Jacoby, D. R., X. O. Breakefield, and D. S. Latchman. 1995. Construction of an HSV-1 amplicon with an inducible Oct-2 operon to modulate cytopathic effect. In Proceedings, International Conference on Gene Therapy for CNS Disorders, Abstract 1.31.
49. Johnson, P. A., K. Yoshida, F. H. Gage, et al. 1992. Effects of gene transfer into cultured CNS neurons with a replication-defective herpes simplex virus type 1 vector. Mol. Brain Res. 12: 95-102.
50. Kaplitt, M. G., A. D. Kwong, S. P. Kleopoulos, et al. 1994. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. USA 19: 8979-8983.
51. Kaplitt, M. G., P. Leone, R. J. Samulski, et al. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. 8: 148-154.
52. Kozarsky, K. F., and J. M. Wilson. 1993. Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3: 499-503.
53. Kozarsky, K. F., M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somat. Cell Mol. Genet. 19: 449-458.
54. Kroll, R. A., M. A. Pagel, L. L. Muldoon, et al. 1996. Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurgery 38: 746-754.
55. Laskowitz, D. T., M. R. Sperling, J. A. French, et al. 1995. The syndrome of frontal lobe epilepsy: Characteristics and surgical management. Neurology 45: 780-787.
56. Le Gal La Salle, G., J. J. Robert, S. Berrard, et al. 1993. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259: 988-990.
57. Levallois, C., A. Privat, and J. Mallet. 1994. Adenovirus insertion encoding the Lac Z gene in human nervous cells in primary dissociated cultures. Compt. Rend. I Acad. Sci. Ser. 3 Sci. Vie 317: 495-498.
58. Lieberman, D. M., D. W. Laske, P. F. Morrison, et al. 1995. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82: 1021-1029.
59. Lu, B., and H. J. Federoff. 1995. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum. Gene Ther. 6: 419-428.
60. A receptor channels. Annu. Rev. Neurosci. 17: 569-602.
61. Margerison, J. H., and J. A. N. Corsellis. 1966. Epilepsy and the temporal lobes. Brain 89: 499-530.
62. Marshall, E. 1996. New Zealand's leap into gene therapy. Science 271: 1489-1490.
63. Martin, D. L., and K. Rimvall. 1993. Regulation of γ-aminobutyric acid synthesis in the brain. J. Neurochem. 60: 395-107.
64. Masukawa, L. M., K. Uruno, M. Sperling, et al. 1992. The functional relationship between antidromically evoked field responses of the dentate gyrus and mossy fiber reorganization in temporal lobe epileptic patients. Brain Res. 579: 119-127.
65. Mathern, G. W., T. L. Babb, J. K. Pretorius, et al. 1995. The pathophysiologic relationships between lesion pathology, intra-cranial ictal EEG onsets, and hippocampal neuron losses in temporal lobe epilepsy. Epilepsy Res. 21: 133-147.
66. Mattson, R. H., O. Petroff, D. Rothman, et al. 1994. Vigabatrin: Effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 35(Suppl. 5): S29-S32.
67. Muldoon, L. L., G. Nilaver, R. A. Kroll, et al. 1995. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147: 1840-1851.
68. Mumford, J. P., and D. J. Cannon. 1994. Vigabatrin. Epilepsia 35(Suppl 5): S25-S8.
69. Nabel, G. J. 1992. Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum. Gene Ther. 3: 399-410.
70. New, K. C., S. D. Rabkin, R. L. Martuza, et al. 1995. Defective HSV vectors for the study of glutamic acid decarboxylase (GAD) expression in cells of the CNS. In Proceedings, International Conference on Gene Therapy for CNS Disorders, Abstract 1.33.
71. O'Connor, W. M., A. Freese, C. R. Lippman, et al. 1995. Preferential transgene expression in dividing glial cells using adenovirus vectors: implications for CNS gene therapy. In Congress of Neurological Surgeons, Abstract 310.
72. O'Connor, W. M., L. M. Masukawa, A. Freese, et al. 1996. Hippocampal cell distributions in temporal lobe epilepsy: A comparison between patients with and without an early risk factor. Epilepsia 37: 440-449.
73. Olsen, R. W., and A. J. Tobin. 1990. Molecular biology of GABAA receptors. FASEB J. 4: 1469-1480.
74. Olsen, R. W., M. Bureau, C. R. Houser, et al. 1992. GABA/ benzodiazepine receptors in human focal epilepsy. In Neurotransmitters in Epilepsy (G. Avanzini, J. Engel, Jr., R. Fariello, and U. Heinemann, Eds.), Epilepsy Res. Suppl. 8: 383-391.
75. Ooboshi, H., M. J. Welsh, C. D. Rios, et al. 1995. Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue. Circ. Res. 77: 7-13.
76. Pennachio, L. A., A. E. Lehesjoki, N. E. Stone, et al. 1996. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271: 1731-1734.
77. Perez-Cruet, M. J., T. W. Trask, S. H. Chen, et al. 1994. Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39: 506-511.
78. Philips, H. A., I. E. Scheffer, S. F. Berkovic, et al. 1995. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2. Nature Genet. 10: 117-118.
79. Polenzani, L., R. M. Woodward, and R. Miledi. 1991. Expression of mammalian γ-aminobutyric acid receptors with distinct pharmacology in Xenopus oocytes. Proc. Natl. Acad. Sci. USA 88: 4318-4322.
80. Quesney, L. F., F. Cendes, A. Olivier, et al. 1995. Intracranial electroencephalographic investigation in frontal lobe epilepsy. Adv. Neurol. 66: 243-258.
81. Qume, M., P. S. Whitton, and L. J. Fowler. 1995. The effect of chronic treatment with the GABA transaminase inhibitors gamma-vinyl-GABA and ethanolamine-o-sulphate on the in vivo release of GABA from rat hippocampus. J. Neurochem. 64: 2256-2261.
82. Redmond, D. E., Jr., K. L. O'Malley, M. G. Kaplitt, et al. 1995. AAV vectored gene therapy in primate parkinson's model. Soc. Neurosci. Abstr. 21: 224.22.
83. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc. Natl. Acad. Sci. USA 90: 5662-5666.
84. Salanova, V., H. H. Morris, P. Van Ness, et al. 1995. Frontal lobe seizures: Electroclinical syndromes. Epilepsia 36: 16-24.
85. A receptor subunits: Role of the δ-subunit. J. Neurosci. 14: 7077-7086.
86. Schwartzkroin, P. A. 1994. Cellular electrophysiology of human epilepsy. Epilepsy Res. 17: 185-192.
87. Shewach, D. S., L. K. Zerbe, T. L. Hughes, et al. 1994. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther. 1: 107-112.
88. Lys mutation. Cell 61: 931-937.
89. Shuaib, A., S. Ijaz, S. Hasan, et al. 1992. Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain Res. 590: 13-17.
90. Sloviter, R. S. 1994. On the relationship between neuropathology and pathophysiology in the epileptic hippocampus of humans and experimental animals. Hippocampus 4: 250-253.
91. Snodgrass, S. R. 1992. GABA and epilepsy: Their complex relationship and the evolution of our understanding. J. Child Neurol. 7: 77-86.
92. Song, S., P. Leone, Y. Wang, et al. 1993. Rotational behavior in adult rats is induced by selective activation of the protein kinase C pathway in substantia nigra pars compacta neurons with a HSV-1 vector. Soc. Neurosci. Abstr. 19: 328.2.
93. Spencer, D. D., and S. S. Spencer. 1985. Surgery for epilepsy. Neurol. Clin. 3: 313-330.
94. Sperling, M. R., M. J. O'Connor, A. J. Saykin, et al. 1992. A non-invasive protocol for anterior temporal lobectomy. Neurology 42: 416-422.
95. Sperling, M. R., M. J. O'Connor, A. J. Saykin, et al. 1996. Temporal lobectomy for refractory epilepsy. JAMA 276: 470-475.
96. Steinlein, O. K., J. C. Mulley, P. Propping, et al. 1995. A missense mutation in the neuronal nicotinic acetylcholine receptor α4-subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genet. 11: 201-203.
97. Strowbridge, B. W., L. M. Masukawa, D. D. Spencer, et al. 1992. Hyperexcitability associated with localizable lesions in epileptic patients. Brain Res. 587: 158-163.
98. Suhr, S. T., and F. H. Gage. 1993. Gene therapy for neurologic disease. Arch. Neurol. 50: 1252-1268.
99. Swartz, B. E., E. Halgren, A. V. Delgado-Escueta, et al. 1989. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilesia 30: 547-558.
100. Tillakaratne, N. J., L. Medina-Kauwe, and K. M. Gibson. 1995. Gamma-aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comp. Biochem. Physiol. 112A: 247-263.
101. Tsai, M. L., G. E. Chatrian, F. Paur, et al. 1993. Electrocorticography in patients with medically intractable temporal lobe seizures. I. Quantification of epileptiform discharges prior to resective surgery. Electroencephalogr. Clin. Neurophysiol. 87: 10-24.
102. Uruno, K., M. J. O'Connor, and L. M. Masukawa. 1994. Alterations of inhibitory synaptic responses in the dentate gyrus of temporal lobe epileptic patients. Hippocampus 4: 583-593.
103. Uruno, K., M. J. O'Connor, and L. M. Masukawa. 1995. Effects of bicuculline and baclofen on paired-pulse depression in the dentate gyrus of epileptic patients. Brain Res. 695: 163-172.
104. Van Ginkel, F. W., C. Liu, J. W. Simecka, et al. 1995. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther. 6: 895-903.
105. Wettstein, J. G., B. Earley, and J. L. Junien. 1995. Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther. 65: 397-114.
106. Wilensky, R. L., K. L. March, I. Gradus-Pizlo, et al. 1995. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am. Heart J. 129: 852-859.
107. Williamson, P. D., J. A. French, V. M. Thadani, et al. 1993. Characteristics of medial temporal lobe epilepsy. II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology. Ann. Neurol. 34: 781-787.
108. Wilson, J. M. 1993. Cystic fibrosis: Vehicles for gene therapy. Nature 365: 691-692.
109. Wilson, J. M., J. F. Englehardt, M. Grossman, et al. 1994. Gene therapy of cystic fibrosis lung disease using El deleted adenoviruses: a phase I trial. Hum. Gene Ther. 5: 501-519.
110. B receptors in physiology and pathology. Neuropsychology 6: 201-214.
111. Wolfe, J. H., S. L. Deshmane, and N. W Fraser. 1982. Herpesvirus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice. Nature Genet. 1: 379.
112. Wong, S. C., M. A. Moffat, and K. L. O'Malley. 1994. Sequences distal to the AP1/E box motif are involved in the cell type-specific expression of the rat tyrosine hydroxylase gene. J. Neurochem. 62: 1691-1697.
113. Wong, S. C., M. A. Moffat, G. T. Coker, et al. 1995. The 3′ flanking region of the human tyrosine hydroxylase gene directs reporter gene expression in peripheral neuroendocrine tissues. J. Neurochem. 65: 23-31.
114. Yang, Y., F. A. Nunes, K. Berencsi, et al. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7: 362-369.
115. Yang, Y. P., F. A. Nunes, K. Berencsi, et al. 1994. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91: 4407-4411.
116. Yei, S., N. Mittereder, K. Tang, et al. 1994. Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1: 192-201.
117. Zabner, J., L. A. Couture, R. J. Gregory, et al. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75: 207-216.